Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by core biosimilars and new launches like subcutaneous infliximab.
Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as ...
Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing ...
The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug ...
On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, ...
At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence ...
Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing ...
Number 4: Regulatory experts and representatives from some of the top biosimilar manufacturers emphasized the importance of ...
Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback